Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in Eur Urol

Retrieve available abstracts of 361 articles:
HTML format
Text format



Single Articles


    May 2017
  1. WILT TJ, Dahm P
    Value of Prostate Cancer Care: New Information on New Therapies Suggest Less is More.
    Eur Urol. 2017 May 20. pii: S0302-2838(17)30402.
    PubMed     Text format    


  2. COOPERBERG MR
    The New US Preventive Services Task Force "C" Draft Recommendation for Prostate Cancer Screening.
    Eur Urol. 2017 May 20. pii: S0302-2838(17)30401.
    PubMed     Text format     Abstract available


  3. WANG R, Sun Y, Li L, Niu Y, et al
    Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9(R) to Suppress Enzalutamide-resistant Prostate Cancer Progression.
    Eur Urol. 2017 May 18. pii: S0302-2838(17)30285.
    PubMed     Text format     Abstract available


  4. NGUYEN PL, Haddad Z, Ross AE, Martin NE, et al
    Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.
    Eur Urol. 2017 May 18. pii: S0302-2838(17)30390.
    PubMed     Text format     Abstract available


  5. HERMANNS T, Poyet C
    The Next Generation of Prostate Cancer Risk Calculators.
    Eur Urol. 2017 May 15. pii: S0302-2838(17)30387.
    PubMed     Text format    


  6. BECK M, Hayoz S, Ghadjar P
    Re: Radiation With or Without Antiandrogen Therapy in Recurrent Prostate Cancer.
    Eur Urol. 2017 May 15. pii: S0302-2838(17)30385.
    PubMed     Text format    


  7. HADASCHIK B, Herrmann K
    Re: Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-ligand-PET/CT Before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
    Eur Urol. 2017 May 15. pii: S0302-2838(17)30388.
    PubMed     Text format    


  8. CHUA MLK, Lo W, Pintilie M, Murgic J, et al
    A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.
    Eur Urol. 2017 May 13. pii: S0302-2838(17)30344.
    PubMed     Text format     Abstract available


  9. MITRAKAS L
    Re: Pascal Rischmann, Albert Gelet, Benjamin Riche, et al. Focal High Intensity Focused Ultrasound of Unilateral Localized Prostate cancer: A Prospective Multicentric Hemiablation Study of 111 Patients. Eur Urol 2017;71:267-73.
    Eur Urol. 2017 May 10. pii: S0302-2838(17)30345.
    PubMed     Text format    


  10. MIRTTI T, Aittokallio T
    Re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40.
    Eur Urol. 2017 May 9. pii: S0302-2838(17)30340.
    PubMed     Text format    


  11. SEYEDNASROLLAH F, Mahmoudian M, Rautakorpi L, Hirvonen O, et al
    Reply to Tuomas Mirtti and Tero Aittokallio's Letter to the Editor re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prost
    Eur Urol. 2017 May 9. pii: S0302-2838(17)30341.
    PubMed     Text format    


    April 2017
  12. YANG JC, Evans CP
    Adjunct Screening of NKX3.1 Expression Supports 5alpha-Reductase Inhibition Intervention in Prostate Cancer Active Surveillance.
    Eur Urol. 2017 Apr 25. pii: S0302-2838(17)30327.
    PubMed     Text format    


  13. PATEL DN, Freedland SJ
    New Prostate Cancer Biomarkers: The Search Continues.
    Eur Urol. 2017 Apr 24. pii: S0302-2838(17)30293.
    PubMed     Text format    


  14. WALSH PC
    The Search for the Missing Heritability of Prostate Cancer.
    Eur Urol. 2017 Apr 22. pii: S0302-2838(17)30283.
    PubMed     Text format     Abstract available


  15. GRUMMET JP, Plass K, N'Dow J
    Prostate Cancer Management in an Ageing Population.
    Eur Urol. 2017 Apr 19. pii: S0302-2838(17)30290.
    PubMed     Text format    


  16. SOORIAKUMARAN P, Nyberg T, Akre O, Widmark A, et al
    Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy.
    Eur Urol. 2017 Apr 14. pii: S0302-2838(17)30282.
    PubMed     Text format     Abstract available


  17. SOOD A, Abdollah F
    Re: Diagnostic Accuracy of Multi-parametric Magnetic Resonance Imaging and Transrectal Ultrasound Biopsy in Prostate Cancer (PROMIS): A Paired Validating Confirmatory Study.
    Eur Urol. 2017 Apr 12. pii: S0302-2838(17)30275.
    PubMed     Text format    


  18. WOO S, Suh CH, Kim SY, Cho JY, et al
    Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis.
    Eur Urol. 2017 Apr 12. pii: S0302-2838(17)30273.
    PubMed     Text format     Abstract available


  19. GANDAGLIA G, Fossati N, Zaffuto E, Bandini M, et al
    Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer.
    Eur Urol. 2017 Apr 12. pii: S0302-2838(17)30280.
    PubMed     Text format     Abstract available


  20. WALKER SM, Knight LA, McCavigan AM, Logan GE, et al
    Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology.
    Eur Urol. 2017 Apr 10. pii: S0302-2838(17)30238.
    PubMed     Text format     Abstract available


  21. RADTKE JP, Wiesenfarth M, Kesch C, Freitag MT, et al
    Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
    Eur Urol. 2017 Apr 8. pii: S0302-2838(17)30267.
    PubMed     Text format     Abstract available


  22. KARNES RJ, Choeurng V, Ross AE, Schaeffer EM, et al
    Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.
    Eur Urol. 2017 Apr 8. pii: S0302-2838(17)30264.
    PubMed     Text format     Abstract available


  23. KLEIN EA, Chait A, Hafron JM, Kernen KM, et al
    The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary
    Eur Urol. 2017 Apr 7. pii: S0302-2838(17)30236.
    PubMed     Text format     Abstract available



  24. Prostate Cancer and the John West Effect.
    Eur Urol. 2017 Apr 3. pii: S0302-2838(17)30095.
    PubMed     Text format     Abstract available


  25. LEYH-BANNURAH SR, Gazdovich S, Budaus L, Zaffuto E, et al
    Local Therapy Improves Survival in Metastatic Prostate Cancer.
    Eur Urol. 2017 Apr 3. pii: S0302-2838(17)30231.
    PubMed     Text format     Abstract available


  26. DUTTA A, Panja S, Virk RK, Kim JY, et al
    Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5alpha-reductase Inhibition.
    Eur Urol. 2017 Apr 3. pii: S0302-2838(17)30252.
    PubMed     Text format     Abstract available


    March 2017
  27. SCHROECK FR, Jacobs BL, Bhayani SB, Nguyen PL, et al
    Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy.
    Eur Urol. 2017 Mar 30. pii: S0302-2838(17)30239.
    PubMed     Text format     Abstract available


  28. KIM JH, Khandwala YS, Chung BI
    Re: Jim C. Hu, David M. Nanus, Art Sedrakyan. Increase in prostate cancer metastases at radical prostatectomy in the United States. Eur Urol 2017;71:147-9.
    Eur Urol. 2017 Mar 29. pii: S0302-2838(17)30234.
    PubMed     Text format    


  29. SCHWEIZER MT, Antonarakis ES, Denmeade SR
    Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer.
    Eur Urol. 2017 Mar 29. pii: S0302-2838(17)30233.
    PubMed     Text format     Abstract available


  30. PORTER LH, Lawrence MG, Ilic D, Clouston D, et al
    Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories.
    Eur Urol. 2017 Mar 22. pii: S0302-2838(17)30178.
    PubMed     Text format     Abstract available


  31. LAMB BW, Violet J, Siva S, Murphy DG, et al
    Re: Radiation With or Without Antiandrogen Therapy in Recurrent Prostate Cancer.
    Eur Urol. 2017 Mar 20. pii: S0302-2838(17)30179.
    PubMed     Text format    


  32. MOLDOVAN PC, Van den Broeck T, Sylvester R, Marconi L, et al
    What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.
    Eur Urol. 2017 Mar 20. pii: S0302-2838(17)30115.
    PubMed     Text format     Abstract available


  33. MO F, Lin D, Takhar M, Ramnarine VR, et al
    Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.
    Eur Urol. 2017 Mar 19. pii: S0302-2838(17)30166.
    PubMed     Text format     Abstract available


  34. ALONGI F, Aiello D, Mazzola R, Cavalleri S, et al
    Re: Giorgio Gandaglia, Alberto Briganti, Noel Clarke, et al. Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.01.039.
    Eur Urol. 2017 Mar 15. pii: S0302-2838(17)30169.
    PubMed     Text format    


  35. MOSCHINI M, Carroll PR, Eggener SE, Epstein JI, et al
    Low-risk Prostate Cancer: Identification, Management, and Outcomes.
    Eur Urol. 2017 Mar 15. pii: S0302-2838(17)30174.
    PubMed     Text format     Abstract available


  36. SMITH MR, Saad F, Rathkopf DE, Mulders PF, et al
    Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    Eur Urol. 2017 Mar 14. pii: S0302-2838(17)30172.
    PubMed     Text format     Abstract available


  37. ANTONARAKIS ES
    Germline DNA Repair Mutations and Response to Hormonal Therapy in Advanced Prostate Cancer.
    Eur Urol. 2017 Mar 14. pii: S0302-2838(17)30167.
    PubMed     Text format    


  38. MONTIRONI R, Lopez-Beltran A, Cheng L, Gasparrini S, et al
    Re: Kenneth A. Iczkowski's Letter to the Editor re: Re: Rodolfo Montironi, Silvia Gasparrini, Roberta Mazzucchelli, et al's Letter to the Editor re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting
    Eur Urol. 2017 Mar 11. pii: S0302-2838(17)30127.
    PubMed     Text format    


  39. ICZKOWSKI KA
    Re: Rodolfo Montironi, Silvia Gasparrini, Roberta Mazzucchelli, et al's Letter to the Editor re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. Eur Urol 2
    Eur Urol. 2017 Mar 8. pii: S0302-2838(17)30128.
    PubMed     Text format    


  40. MURPHY DG, Sweeney CJ, Tombal B
    "Gotta Catch 'em All", or Do We? Pokemet Approach to Metastatic Prostate Cancer.
    Eur Urol. 2017 Mar 7. pii: S0302-2838(17)30131.
    PubMed     Text format     Abstract available


  41. ANNALA M, Struss WJ, Warner EW, Beja K, et al
    Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
    Eur Urol. 2017 Mar 1. pii: S0302-2838(17)30112.
    PubMed     Text format     Abstract available


  42. REIG O, Marin-Aguilera M, Carrera G, Jimenez N, et al
    Corrigendum re: "TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer" [Eur Urol 2016;70:709-13].
    Eur Urol. 2017 Mar 1. pii: S0302-2838(17)30116.
    PubMed     Text format    


    February 2017
  43. VENDERINK W, van Luijtelaar A, Bomers JG, van der Leest M, et al
    Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate Cancer.
    Eur Urol. 2017 Feb 28. pii: S0302-2838(17)30110.
    PubMed     Text format     Abstract available


  44. TAAFFE DR, Newton RU, Spry N, Joseph D, et al
    Effects of Different Exercise Modalities on Fatigue in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Year-long Randomised Controlled Trial.
    Eur Urol. 2017 Feb 26. pii: S0302-2838(17)30108.
    PubMed     Text format     Abstract available


  45. KAPOOR J, Lamb AD, Murphy DG
    Re: Diagnostic Accuracy of Multi-parametric MRI and TRUS Biopsy in Prostate Cancer (PROMIS): A Paired Validating Confirmatory Study.
    Eur Urol. 2017 Feb 23. pii: S0302-2838(17)30103.
    PubMed     Text format    


  46. MATEO J, Sharp A, de Bono JS
    Investigating Genomic Aberrations of the Androgen Receptor: Moving Closer to More Precise Prostate Cancer Care?
    Eur Urol. 2017 Feb 20. pii: S0302-2838(17)30094.
    PubMed     Text format    


  47. JONES TA, Marks LS
    Re: A Pilot Study to Evaluate the Role of Magnetic Resonance Imaging for Prostate Cancer Screening in the General Population.
    Eur Urol. 2017 Feb 20. pii: S0302-2838(17)30101.
    PubMed     Text format    


  48. SPRATT DE, Lee JY, Dess RT, Narayana V, et al
    Vessel-sparing Radiotherapy for Localized Prostate Cancer to Preserve Erectile Function: A Single-arm Phase 2 Trial.
    Eur Urol. 2017 Feb 20. pii: S0302-2838(17)30096.
    PubMed     Text format     Abstract available


  49. MOURACADE P
    Re: Giorgio Gandaglia, Nicola Fossati, Armando Stabile, et al. Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2
    Eur Urol. 2017 Feb 18. pii: S0302-2838(17)30085.
    PubMed     Text format    


  50. PRUTHI DK, Ankerst DP, Liss MA
    Novel Definitions of Low-risk and High-risk Prostate Cancer: Implications for the European Randomized Study of Screening for Prostate Cancer Risk Assessment Tool.
    Eur Urol. 2017 Feb 17. pii: S0302-2838(17)30098.
    PubMed     Text format    


  51. DAL MORO F, Motterle G, Barbieri L, Zattoni F, et al
    Re: Jean-Pierre Droz, Gilles Albrand, Silke Gillessen, et al. Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo
    Eur Urol. 2017 Feb 15. pii: S0302-2838(17)30088.
    PubMed     Text format    


  52. GANDAGLIA G, Fossati N, Montorsi F, Briganti A, et al
    Reply to Pascal Mouracade's Letter to the Editor re: Giorgio Gandaglia, Nicola Fossati, Armando Stabile, et al. Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up. Eur Uro
    Eur Urol. 2017 Feb 14. pii: S0302-2838(17)30086.
    PubMed     Text format    


  53. COZZARINI C, Benigni F, Fiorino C, Mondino A, et al
    Reply to Salvador Vale's Letter to the Editor re: Cesare Cozzarini. Whole-pelvis Radiotherapy in the Radiation Treatment of Intermediate- and High-risk Prostate Cancer: How to Improve the Therapeutic Ratio of a Potentially Effective but still Unsatisf
    Eur Urol. 2017 Feb 14. pii: S0302-2838(17)30090.
    PubMed     Text format    


  54. VALE S
    Re: Cesare Cozzarini. Whole-pelvis Radiotherapy in the Radiation Treatment of Intermediate- and High-risk Prostate Cancer: How to Improve the Therapeutic Ratio of a Potentially Effective but still Unsatisfactory Treatment? Eur Urol 2017;71:44-5: Precl
    Eur Urol. 2017 Feb 14. pii: S0302-2838(17)30089.
    PubMed     Text format    


  55. WOO S, Suh CH, Kim SY, Cho JY, et al
    Diagnostic Performance of Prostate Imaging Reporting and Data System Version 2 for Detection of Prostate Cancer: A Systematic Review and Diagnostic Meta-analysis.
    Eur Urol. 2017 Feb 11. pii: S0302-2838(17)30067.
    PubMed     Text format     Abstract available


  56. SEYEDNASROLLAH F, Mahmoudian M, Rautakorpi L, Hirvonen O, et al
    How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer?
    Eur Urol. 2017 Feb 8. pii: S0302-2838(17)30068.
    PubMed     Text format    


  57. DOWNER MK, Allard CB, Preston MA, Gaziano JM, et al
    Regular Aspirin Use and the Risk of Lethal Prostate Cancer in the Physicians' Health Study.
    Eur Urol. 2017 Feb 8. pii: S0302-2838(17)30069.
    PubMed     Text format     Abstract available


  58. GANDAGLIA G, Briganti A, Clarke N, Karnes RJ, et al
    Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients.
    Eur Urol. 2017 Feb 8. pii: S0302-2838(17)30064.
    PubMed     Text format     Abstract available


  59. DU C, Chen H, Li C
    Re: Alessandro Morlacco, John C. Cheville, Laureano J. Rangel, Derek J. Gearman, R. Jeffrey Karnes. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-risk" Prostate Cancer: Implications for Active Surveillance. Eur Urol. In press
    Eur Urol. 2017 Feb 3. pii: S0302-2838(17)30065.
    PubMed     Text format    


  60. AHMAD AE, Finelli A
    Active Surveillance Discussion for Low-risk Prostate Cancer: Patients' Preferences and Counseling Techniques.
    Eur Urol. 2017 Feb 2. pii: S0302-2838(17)30060.
    PubMed     Text format    


  61. ROOBOL MJ, Verbeek JF, van der Kwast T, Kummerlin IP, et al
    Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
    Eur Urol. 2017 Feb 2. pii: S0302-2838(17)30058.
    PubMed     Text format     Abstract available


  62. SIVARAMAN A, Barret E
    Reply to Runqiang Yuan and Hongxing Huang's Letter to the Editor re: Ernesto R. Cordeiro Feijoo, Arjun Sivaraman, Eric Barret, et al. Focal High-intensity Focused Ultrasound Targeted Hemiablation for Unilateral Prostate Cancer: A Prospective Evaluatio
    Eur Urol. 2017 Feb 1. pii: S0302-2838(17)30059.
    PubMed     Text format    


    January 2017
  63. MURPHY DG, Risbridger GP, Bristow RG, Sandhu S, et al
    The Evolving Narrative of DNA Repair Gene Defects: Distinguishing Indolent from Lethal Prostate Cancer.
    Eur Urol. 2017 Jan 25. pii: S0302-2838(17)30043.
    PubMed     Text format    


  64. MICHEL MC
    Re: The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.
    Eur Urol. 2017 Jan 25. pii: S0302-2838(17)30047.
    PubMed     Text format    


  65. EHDAIE B, Assel M, Benfante N, Malhotra D, et al
    A Systematic Approach to Discussing Active Surveillance with Patients with Low-risk Prostate Cancer.
    Eur Urol. 2017 Jan 24. pii: S0302-2838(17)30002.
    PubMed     Text format     Abstract available


  66. FOSSATI N, Willemse PM, van den Bergh RC, Van den Broeck T, et al
    The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review.
    Eur Urol. 2017 Jan 23. pii: S0302-2838(16)30900.
    PubMed     Text format     Abstract available


  67. EPSTEIN JI, Trock B, Han M
    Reply to Christian Daniel Fankhauser, Lorelei A. Mucci, and Travis A. Gerke's Letter to the Editor re: Won Sik Ham, Heather J. Chalfin, Zhaoyong Feng, et al. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason
    Eur Urol. 2017 Jan 17. pii: S0302-2838(17)30011.
    PubMed     Text format    


  68. FANKHAUSER CD, Mucci LA, Gerke TA
    Re: Won Sik Ham, Heather J. Chalfin, Zhaoyong Feng, et al. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.11.006.
    Eur Urol. 2017 Jan 17. pii: S0302-2838(17)30032.
    PubMed     Text format    


  69. KALLIDONIS P, Liatsikos E
    Re: Long-term Results of Active Surveillance in the Goteborg Randomized, Population-based Prostate Cancer Screening Trial.
    Eur Urol. 2017 Jan 16. pii: S0302-2838(17)30014.
    PubMed     Text format    


  70. ZILLI T, Crehange G, Chapet O
    Re: Pascal Rischmann, Albert Gelet, Benjamin Riche, et al. Focal High Intensity Focused Ultrasound of Unilateral Localized Prostate Cancer: A Prospective Multicentric Hemiablation Study of 111 Patients. Eur Urol. In press. http://dx.doi.org/10.1016/j.
    Eur Urol. 2017 Jan 16. pii: S0302-2838(17)30016.
    PubMed     Text format    


  71. DE LAERE B, van Dam PJ, Whitington T, Mayrhofer M, et al
    Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns.
    Eur Urol. 2017 Jan 16. pii: S0302-2838(17)30018.
    PubMed     Text format     Abstract available


  72. GIANNARINI G, Crestani A, Rossanese M, Ficarra V, et al
    Multiparametric Magnetic Resonance Imaging Targeted Biopsy for Early Detection of Prostate Cancer: All That Glitters Is Not Gold!
    Eur Urol. 2017 Jan 13. pii: S0302-2838(17)30017.
    PubMed     Text format    


  73. MAY M, Stief CG, Brookman-May SD
    Re: The Role of Adjuvant Radiotherapy in Pathologically Lymph Node Positive Prostate Cancer.
    Eur Urol. 2017 Jan 13. pii: S0302-2838(17)30013.
    PubMed     Text format    


  74. RISCHMANN P
    Reply to Thomas Zilli, Gilles Crehange and Olivier Chapet's Letter to the Editor re: Pascal Rischmann, Albert Gelet, Benjamin Riche, et al. Focal High Intensity Focused Ultrasound of Unilateral Localized Prostate Cancer: A Prospective Multicentric Hem
    Eur Urol. 2017 Jan 11. pii: S0302-2838(17)30015.
    PubMed     Text format    


  75. DROZ JP, Albrand G, Gillessen S, Hughes S, et al
    Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology.
    Eur Urol. 2017 Jan 11. pii: S0302-2838(17)30001.
    PubMed     Text format     Abstract available


  76. LAMB AD, Lawrence MG, Sandhu S
    Practical Polling for Prostate Cancer: AR-V7-based Treatment Selection.
    Eur Urol. 2017 Jan 11. pii: S0302-2838(17)30004.
    PubMed     Text format    


  77. FODOR A, Fiorino C, Picchio M, Di Muzio N, et al
    Re: Daniel E. Spratt, Herbert A. Vargas, Zachary S. Zumsteg, et al. Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.07.
    Eur Urol. 2017 Jan 5. pii: S0302-2838(16)30925.
    PubMed     Text format    


  78. MCLEOD DG, Srivastava S
    Re: Inherited DNA-repair Gene Mutations in Men with Metastatic Prostate Cancer.
    Eur Urol. 2017 Jan 5. pii: S0302-2838(16)30922.
    PubMed     Text format    


  79. SCHOUTEN MG, van der Leest M, Pokorny M, Hoogenboom M, et al
    Why and Where do We Miss Significant Prostate Cancer with Multi-parametric Magnetic Resonance Imaging followed by Magnetic Resonance-guided and Transrectal Ultrasound-guided Biopsy in Biopsy-naive Men?
    Eur Urol. 2017 Jan 4. pii: S0302-2838(16)30903.
    PubMed     Text format     Abstract available


    December 2016
  80. SUARDI N, Briganti A, Gandaglia G, Fossati N, et al
    Salvage Lymph Node Dissection for Node-only Recurrence of Prostate Cancer: Ready for Prime Time?
    Eur Urol. 2016 Dec 30. pii: S0302-2838(16)30898.
    PubMed     Text format     Abstract available


  81. EPSTEIN JI
    Prostate Cancer Grade Groups Correlate with Prostate-specific Cancer Mortality: SEER Data for Contemporary Graded Specimens.
    Eur Urol. 2016 Dec 28. pii: S0302-2838(16)30918.
    PubMed     Text format    


  82. SCHIFF JP, Lewis BE, Ledet EM, Sartor O, et al
    Prostate-specific Antigen Response and Eradication of Androgen Receptor Amplification with High-dose Testosterone in Prostate Cancer.
    Eur Urol. 2016 Dec 28. pii: S0302-2838(16)30912.
    PubMed     Text format    


  83. GILD P, von Landenberg N, Cole AP
    Re: Phillip J. Gray, Chun Chieh Lin, Matthew R. Cooperberg, Ahmedin Jemal, Jason A. Efstathiou. Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer. Eur Urol. In press. http://dx.d
    Eur Urol. 2016 Dec 28. pii: S0302-2838(16)30906.
    PubMed     Text format    


  84. BENTMAR HOLGERSSON M, Malm J, Lundberg Giwercman Y
    Serum Testosterone Levels in Early Prediction of Prostate Cancer Risk.
    Eur Urol. 2016 Dec 16. pii: S0302-2838(16)30896.
    PubMed     Text format    


  85. ANDERSON BB, Oberlin DT, Razmaria AA, Choy B, et al
    Extraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 Prostate Cancer.
    Eur Urol. 2016 Dec 13. pii: S0302-2838(16)30880.
    PubMed     Text format     Abstract available


  86. SCHER HI, Graf RP, Schreiber NA, McLaughlin B, et al
    Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2016 Dec 12. pii: S0302-2838(16)30857.
    PubMed     Text format     Abstract available


  87. NA R, Zheng SL, Han M, Yu H, et al
    Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.
    Eur Urol. 2016 Dec 9. pii: S0302-2838(16)30885.
    PubMed     Text format     Abstract available


    November 2016
  88. PARKER WP, Karnes RJ, Mynderse LA, Lowe VJ, et al
    Reply from Authors re: Alberto Bossi, Nicolas Mottet, Pierre Blanchard. Choline Positron Emission Tomography/Computed Tomography for Selection of Patients for Salvage Strategies After Primary Local Treatment of Prostate Cancer and Rising Prostate-spec
    Eur Urol. 2016 Nov 30. pii: S0302-2838(16)30855.
    PubMed     Text format    


  89. LIN DW, Newcomb LF, Brown MD, Sjoberg DD, et al
    Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.
    Eur Urol. 2016 Nov 23. pii: S0302-2838(16)30850.
    PubMed     Text format     Abstract available


  90. TUTOLO M, Fossati N, Van der Aa F, Gandaglia G, et al
    Magnetic Resonance Imaging for Membranous Urethral Length Assessment Prior to Radical Prostatectomy: Can it Really Improve Prostate Cancer Management?
    Eur Urol. 2016 Nov 22. pii: S0302-2838(16)30811.
    PubMed     Text format    


  91. SUNDI D, Schaeffer EM
    Progress in Prognosis and Prediction for Men with Prostate Cancer.
    Eur Urol. 2016 Nov 22. pii: S0302-2838(16)30761.
    PubMed     Text format    


  92. HAM WS, Chalfin HJ, Feng Z, Trock BJ, et al
    New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.
    Eur Urol. 2016 Nov 19. pii: S0302-2838(16)30806.
    PubMed     Text format     Abstract available


  93. WALLIS CJ, Satkunasivam R, Nam RK
    Postoperative Radiotherapy in Locally Advanced Prostate Cancer: A Question of Who and When.
    Eur Urol. 2016 Nov 17. pii: S0302-2838(16)30810.
    PubMed     Text format    


  94. KANABUR P, Scovell JM, Ramasamy R
    Re: Vasectomy and Prostate Cancer Incidence and Mortality in a Large US Cohort.
    Eur Urol. 2016 Nov 16. pii: S0302-2838(16)30808.
    PubMed     Text format    


  95. DE REIJKE TM, van Moorselaar JR
    Re: Ten-year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.
    Eur Urol. 2016 Nov 15. pii: S0302-2838(16)30805.
    PubMed     Text format    


  96. DA SILVA FC, Oliveira P
    Tumor clone dynamics in lethal prostate cancer.
    Eur Urol. 2016 Nov 15. pii: S0302-2838(16)30800.
    PubMed     Text format    


  97. BOSSI A, Mottet N, Blanchard P
    Choline Positron Emission Tomography/Computed Tomography for Selection of Patients for Salvage Strategies After Primary Local Treatment of Prostate Cancer and Rising Prostate-specific Antigen: Ready for Prime Time?
    Eur Urol. 2016 Nov 11. pii: S0302-2838(16)30793.
    PubMed     Text format    


  98. KANABUR P, Scovell JM, Ramasamy R
    Re: Vasectomy and Prostate Cancer Incidence and Mortality in a Large US Cohort.
    Eur Urol. 2016 Nov 9. pii: S0302-2838(16)30759.
    PubMed     Text format    


  99. YUAN R, Huang H
    Re: Ernesto R. Cordeiro Feijoo, Arjun Sivaraman, Eric Barret, et al. Focal High-intensity Focused Ultrasound Targeted Hemiablation for Unilateral Prostate Cancer: A Prospective Evaluation of Oncologic and Functional Outcomes. Eur Urol 2016;69:214-20.
    Eur Urol. 2016 Nov 8. pii: S0302-2838(16)30758.
    PubMed     Text format    


  100. COOPERBERG MR
    Re: 10-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.
    Eur Urol. 2016 Nov 3. pii: S0302-2838(16)30751.
    PubMed     Text format    


  101. TYSON MD, Alvarez J, Koyama T, Hoffman KE, et al
    Racial Variation in Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Results from the CEASAR Study.
    Eur Urol. 2016 Nov 2. pii: S0302-2838(16)30750.
    PubMed     Text format     Abstract available


  102. VAN HEMELRIJCK M, Garmo H, Lindhagen L, Bratt O, et al
    Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer.
    Eur Urol. 2016 Nov 2. pii: S0302-2838(16)30745.
    PubMed     Text format     Abstract available


  103. COOPERBERG MR
    What Early ProtecT Results Have Confirmed About Risk-stratified Prostate Cancer Management.
    Eur Urol. 2016 Nov 1. pii: S0302-2838(16)30720.
    PubMed     Text format    


  104. SCHIAVINA R, Bianchi L, Borghesi M, Martorana G, et al
    Salvage Surgery for Nodal Recurrence of Prostate Cancer: Might the Robotic Approach Render an Experimental Procedure More Acceptable?
    Eur Urol. 2016 Nov 1. pii: S0302-2838(16)30747.
    PubMed     Text format    


  105. WILLIAMS SB, Chapin BF
    Patterns of Care for Prostate Cancer Patients: Predictors of Care, But For Whom?
    Eur Urol. 2016 Nov 1. pii: S0302-2838(16)30723.
    PubMed     Text format    


    October 2016
  106. BROOKMAN-MAY SD, May M, Lebentrau S, Klotz T, et al
    Re: Scott P. Kelly, Philip S. Rosenberg, William F. Anderson, et al. Trends in the Incidence of Fatal Prostate Cancer in the United States by Race. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.05.011.
    Eur Urol. 2016 Oct 27. pii: S0302-2838(16)30727.
    PubMed     Text format    


  107. VIDAL AC, Freedland SJ
    Obesity and Prostate Cancer: A Focused Update on Active Surveillance, Race, and Molecular Subtyping.
    Eur Urol. 2016 Oct 19. pii: S0302-2838(16)30714.
    PubMed     Text format     Abstract available


  108. DE BONO J
    Reply to Robert J. van Soest and Ronald de Wit's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant
    Eur Urol. 2016 Oct 14. pii: S0302-2838(16)30699.
    PubMed     Text format    


  109. VAN SOEST RJ, de Wit R
    Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press.
    Eur Urol. 2016 Oct 13. pii: S0302-2838(16)30700.
    PubMed     Text format    


  110. STATTIN P, Bratt O
    Reply to Glen D. Santok and Koon H. Rha' Letter to the Editor re: Par Stattin, Fredrik Sandin, Frederik Birkebaek Thomsen, et al. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationw
    Eur Urol. 2016 Oct 6. pii: S0302-2838(16)30677.
    PubMed     Text format    


  111. JOHNSTON TJ, Shaw GL, Lamb AD, Parashar D, et al
    Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.
    Eur Urol. 2016 Oct 6. pii: S0302-2838(16)30680.
    PubMed     Text format     Abstract available


  112. VILLA S, Kendel F, Venderbos L, Rancati T, et al
    Setting an Agenda for Assessment of Health-related Quality of Life Among Men with Prostate Cancer on Active Surveillance: A Consensus Paper from a European School of Oncology Task Force.
    Eur Urol. 2016 Oct 6. pii: S0302-2838(16)30681.
    PubMed     Text format     Abstract available


  113. RISCHMANN P, Gelet A, Riche B, Villers A, et al
    Focal High Intensity Focused Ultrasound of Unilateral Localized Prostate cancer: A Prospective Multicentric Hemiablation Study of 111 Patients.
    Eur Urol. 2016 Oct 6. pii: S0302-2838(16)30679.
    PubMed     Text format     Abstract available


  114. SYDES MR, Ritchie AW, James ND
    Reply to Che-Kai Tsao, Matthew D. Galsky, and William K. Oh's Platinum Opinion. Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer: Urgent Need To Minimize The Risk Of Neutropenic Fever. Eur Urol 2016;70:707-708.
    Eur Urol. 2016 Oct 6. pii: S0302-2838(16)30676.
    PubMed     Text format    


  115. SANTOK GD, Rha KH
    Re: Par Stattin, Fredrik Sandin, Frederik Birkebaek Thomsen, et al. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study. Eur Urol. In press. http://dx.doi
    Eur Urol. 2016 Oct 4. pii: S0302-2838(16)30678.
    PubMed     Text format    


    September 2016
  116. TEPLY BA, Kachhap S, Eisenberger MA, Denmeade SR, et al
    Extreme Response to High-dose Testosterone in BRCA2- and ATM-mutated Prostate Cancer.
    Eur Urol. 2016 Sep 29. pii: S0302-2838(16)30642.
    PubMed     Text format    


  117. VILLERS A, Rubin MA
    Re: Prognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy.
    Eur Urol. 2016 Sep 26. pii: S0302-2838(16)30639.
    PubMed     Text format    


  118. MATTEI A, Grande P, Di Pierro GB
    Reply from Authors re: Jens Uwe Stolzenburg, Iason Kyriazis, Evangelos Liatsikos. Postoperative Lymphocele Formation after Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy Should Not Be Considered an Inevitable Consequence of the Appr
    Eur Urol. 2016 Sep 22. pii: S0302-2838(16)30658.
    PubMed     Text format    


  119. ROUVIERE O, Chapelon JY, Crouzet S, Gelet A, et al
    Prostate Cancer Focal Therapy: Just Because You Can Does Not Mean You Should.
    Eur Urol. 2016 Sep 21. pii: S0302-2838(16)30660.
    PubMed     Text format    


  120. CRONAUER MV, Merseburger AS, Hoda MR
    Re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur
    Eur Urol. 2016 Sep 20. pii: S0302-2838(16)30643.
    PubMed     Text format    


  121. BERGDAHL AG, Wilderang U, Aus G, Carlsson S, et al
    Corrigendum re: "Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Goteborg Randomised Screening Trial" [Eur Urol 2016;70:566-73].
    Eur Urol. 2016 Sep 20. pii: S0302-2838(16)30636.
    PubMed     Text format    


  122. STEINESTEL J, Bernemann C, Schrader AJ, Lennerz JK, et al
    Reply to Marcus V. Cronauer, Axel S. Merseburger, and M. Raschid Hoda's Letter to the Editor re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Genera
    Eur Urol. 2016 Sep 16. pii: S0302-2838(16)30644.
    PubMed     Text format    


  123. STEINESTEL J, Bernemann C, Schrader AJ, Lennerz JK, et al
    Reply from Authors re: Emmanuel S. Antonarakis, Howard I. Scher. Do Patients With AR-V7-Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.08.038:
    Eur Urol. 2016 Sep 15. pii: S0302-2838(16)30583.
    PubMed     Text format    


  124. WIT EM, Acar C, Grivas N, Yuan C, et al
    Sentinel Node Procedure in Prostate Cancer: A Systematic Review to Assess Diagnostic Accuracy.
    Eur Urol. 2016 Sep 14. pii: S0302-2838(16)30617.
    PubMed     Text format     Abstract available


  125. DALELA D, Karabon P, Sammon J, Sood A, et al
    Generalizability of the Prostate Cancer Intervention Versus Observation Trial (PIVOT) Results to Contemporary North American Men with Prostate Cancer.
    Eur Urol. 2016 Sep 13. pii: S0302-2838(16)30521.
    PubMed     Text format     Abstract available


  126. LIU P, Liu L, Zu X
    Re: Claude Schulman, Erik Cornel, Vsevolod Matveev, et al. Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND). Eur Urol 2016;69:720-7.
    Eur Urol. 2016 Sep 13. pii: S0302-2838(16)30579.
    PubMed     Text format    


  127. MAITLAND NJ
    Re: The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer.
    Eur Urol. 2016 Sep 13. pii: S0302-2838(16)30574.
    PubMed     Text format    


  128. SANCHEZ-SALAS R
    Re: Focal Laser Ablation of Prostate Cancer: Phase I Clinical Trial.
    Eur Urol. 2016 Sep 6. pii: S0302-2838(16)30576.
    PubMed     Text format    


  129. VENTIMIGLIA E, Salonia A, Briganti A, Montorsi F, et al
    Re: Family History and Probability of Prostate Cancer, Differentiated by Risk Category - A Nationwide Population-based Study.
    Eur Urol. 2016 Sep 5. pii: S0302-2838(16)30575.
    PubMed     Text format    


  130. COZZARINI C
    Whole-pelvis Radiotherapy in the Radiation Treatment of Intermediate- and High-risk Prostate Cancer: How to Improve the Therapeutic Ratio of a Potentially Effective but still Unsatisfactory Treatment?
    Eur Urol. 2016 Sep 3. pii: S0302-2838(16)30525.
    PubMed     Text format    


  131. MONTORSI F, Gandaglia G, Fossati N, Suardi N, et al
    Robot-assisted Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer.
    Eur Urol. 2016 Sep 3. pii: S0302-2838(16)30524.
    PubMed     Text format     Abstract available


  132. ISAACS WB
    What Do Myeloma, Breast Cancer, and Prostate Cancer Have in Common?
    Eur Urol. 2016 Sep 3. pii: S0302-2838(16)30531.
    PubMed     Text format    


  133. PARKER WP, Davis BJ, Park SS, Olivier KR, et al
    Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease.
    Eur Urol. 2016 Sep 3. pii: S0302-2838(16)30528.
    PubMed     Text format     Abstract available


  134. GRAY PJ, Lin CC, Cooperberg MR, Jemal A, et al
    Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer.
    Eur Urol. 2016 Sep 2. pii: S0302-2838(16)30520.
    PubMed     Text format     Abstract available


  135. JERECZEK-FOSSA BA
    Re: Stereotactic Body Re-irradiation Therapy for Locally Recurrent Prostate Cancer After External-beam Radiation Therapy: Initial Report.
    Eur Urol. 2016 Sep 2. pii: S0302-2838(16)30532.
    PubMed     Text format    


  136. KIMURA T, Egawa S
    Re: Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
    Eur Urol. 2016 Sep 2. pii: S0302-2838(16)30529.
    PubMed     Text format    


  137. PAPA N, Perera M, Hofman MS, Bolton D, et al
    Reply to Fabio Zattoni, Filiberto Zattoni, and Laura Evangelista's Letter to the Editor re: Marlon Perera, Nathan Papa, Daniel Christidis, et al. Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emi
    Eur Urol. 2016 Sep 2. pii: S0302-2838(16)30523.
    PubMed     Text format    


    August 2016
  138. ANTONARAKIS ES, Scher HI
    Do Patients With AR-V7-Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions.
    Eur Urol. 2016 Aug 31. pii: S0302-2838(16)30505.
    PubMed     Text format    


  139. ZATTONI F, Zattoni F, Evangelista L
    Re: Marlon Perera, Nathan Papa, Daniel Christidis, et al. Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur
    Eur Urol. 2016 Aug 31. pii: S0302-2838(16)30522.
    PubMed     Text format    


  140. SONPAVDE G, Antonarakis ES
    Circulating Tumor Cells in Advanced Prostate Cancer: Time to Move from Prognostic to Predictive Ability.
    Eur Urol. 2016 Aug 31. pii: S0302-2838(16)30526.
    PubMed     Text format    


  141. CORNFORD P, Bellmunt J, Bolla M, Briers E, et al
    EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Eur Urol. 2016 Aug 31. pii: S0302-2838(16)30469.
    PubMed     Text format     Abstract available


  142. MATEO J, Boysen G, Barbieri CE, Bryant HE, et al
    DNA Repair in Prostate Cancer: Biology and Clinical Implications.
    Eur Urol. 2016 Aug 30. pii: S0302-2838(16)30504.
    PubMed     Text format     Abstract available


  143. TRAN GN, Leapman MS, Nguyen HG, Cowan JE, et al
    Magnetic Resonance Imaging-Ultrasound Fusion Biopsy During Prostate Cancer Active Surveillance.
    Eur Urol. 2016 Aug 29. pii: S0302-2838(16)30490.
    PubMed     Text format     Abstract available


  144. BARENTSZ JO, Mulders P, Gerritsen W, Futterer JJ, et al
    Assessing Metastatic Disease in Advanced Prostate Cancer: It's Time to Change Imaging.
    Eur Urol. 2016 Aug 29. pii: S0302-2838(16)30513.
    PubMed     Text format    


  145. MORLACCO A, Sharma V, Viers BR, Rangel LJ, et al
    The Incremental Role of Magnetic Resonance Imaging for Prostate Cancer Staging before Radical Prostatectomy.
    Eur Urol. 2016 Aug 28. pii: S0302-2838(16)30482.
    PubMed     Text format     Abstract available


  146. PORPIGLIA F, Manfredi M, Mele F, Cossu M, et al
    Diagnostic Pathway with Multiparametric Magnetic Resonance Imaging Versus Standard Pathway: Results from a Randomized Prospective Study in Biopsy-naive Patients with Suspected Prostate Cancer.
    Eur Urol. 2016 Aug 27. pii: S0302-2838(16)30509.
    PubMed     Text format     Abstract available


  147. MORLACCO A, Cheville JC, Rangel LJ, Gearman DJ, et al
    Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.
    Eur Urol. 2016 Aug 27. pii: S0302-2838(16)30511.
    PubMed     Text format     Abstract available


  148. GANDAGLIA G, Fossati N, Stabile A, Bandini M, et al
    Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up.
    Eur Urol. 2016 Aug 26. pii: S0302-2838(16)30508.
    PubMed     Text format     Abstract available


  149. DEL RE M, Biasco E, Crucitta S, Derosa L, et al
    The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.
    Eur Urol. 2016 Aug 26. pii: S0302-2838(16)30479.
    PubMed     Text format     Abstract available


  150. MOTTET N, Bellmunt J, Bolla M, Briers E, et al
    EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
    Eur Urol. 2016 Aug 25. pii: S0302-2838(16)30470.
    PubMed     Text format     Abstract available


  151. PORRES D, Heidenreich A, Pfister D
    Re: Pattern of Progression After Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences.
    Eur Urol. 2016 Aug 24. pii: S0302-2838(16)30499.
    PubMed     Text format    


  152. MONTIRONI R, Gasparrini S, Mazzucchelli R, Massari F, et al
    Re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.02.047.
    Eur Urol. 2016 Aug 24. pii: S0302-2838(16)30503.
    PubMed     Text format    


  153. KLIL-DRORI AJ, Azoulay L
    Reply to Mieke Van Hemelrijck, Hans Garmo, Jan Adolfsson, and Par Stattin's Letter to the Editor re: Adi J. Klil-Drori, Hui Yin, Vicky Tagalakis, Armen Aprikian, Laurent Azoulay. Androgen Deprivation Therapy for Prostate Cancer and Risk of Venous Thro
    Eur Urol. 2016 Aug 23. pii: S0302-2838(16)30489.
    PubMed     Text format    


  154. HADASCHIK B
    Re: 225Ac-PSMA-617 for PSMA-Targeting Alpha-radiation Therapy of Patients with Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2016 Aug 20. pii: S0302-2838(16)30495.
    PubMed     Text format    


  155. LAMB AD, Zargar H, Murphy DG, Corcoran NM, et al
    Disrupting the Status Quo in Prostate Cancer Diagnosis.
    Eur Urol. 2016 Aug 20. pii: S0302-2838(16)30485.
    PubMed     Text format    


  156. LOLKEMA M, Debets R, de Wit R
    Prostate Cancer and Immune Monitoring: Are We Heading Towards Better Selection of Patients and Treatment Strategies?
    Eur Urol. 2016 Aug 17. pii: S0302-2838(16)30481.
    PubMed     Text format    


  157. VAN HEMELRIJCK M, Garmo H, Adolfsson J, Stattin P, et al
    Re: Adi J. Klil-Drori, Hui Yin, Vicky Tagalakis, Armen Aprikian, Laurent Azoulay. Androgen Deprivation Therapy for Prostate Cancer and Risk of Venous Thromboembolism. Eur Urol. 2016;70:56-61.
    Eur Urol. 2016 Aug 17. pii: S0302-2838(16)30488.
    PubMed     Text format    


  158. DE BONO JS
    Reply to Giandomenico Roviello, Daniele Generali, and Roberto Petrioli's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastat
    Eur Urol. 2016 Aug 17. pii: S0302-2838(16)30478.
    PubMed     Text format    


  159. ROVIELLO G, Generali D, Petrioli R
    Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press.
    Eur Urol. 2016 Aug 16. pii: S0302-2838(16)30477.
    PubMed     Text format    


  160. COLEY RY, Zeger SL, Mamawala M, Pienta KJ, et al
    Prediction of the Pathologic Gleason Score to Inform a Personalized Management Program for Prostate Cancer.
    Eur Urol. 2016 Aug 11. pii: S0302-2838(16)30472.
    PubMed     Text format     Abstract available


  161. VOGELZANG NJ, Fizazi K, Burke JM, De Wit R, et al
    Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2016 Aug 10. pii: S0302-2838(16)30467.
    PubMed     Text format     Abstract available


  162. MORTEZAVI A, Eberli D
    Re: Prostate Cancer Detection with Magnetic Resonance-ultrasound Fusion Biopsy: The Role of Systematic and Targeted Biopsies.
    Eur Urol. 2016 Aug 5. pii: S0302-2838(16)30455.
    PubMed     Text format    


  163. FRANK C, Sundquist J, Hemminki A, Hemminki K, et al
    Familial Associations Between Prostate Cancer and Other Cancers.
    Eur Urol. 2016 Aug 4. pii: S0302-2838(16)30436.
    PubMed     Text format     Abstract available


  164. HEIDENREICH A, Chowdhury S, Klotz L, Siemens DR, et al
    Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial.
    Eur Urol. 2016 Aug 3. pii: S0302-2838(16)30432.
    PubMed     Text format     Abstract available


  165. YLITALO EB, Thysell E, Jernberg E, Lundholm M, et al
    Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response.
    Eur Urol. 2016 Aug 3. pii: S0302-2838(16)30438.
    PubMed     Text format     Abstract available


  166. GOVOROV A
    Re: More Favorable Pathological Outcomes in Men with Low Risk Prostate Cancer Diagnosed on Repeat Versus Initial Transrectal Ultrasound Guided Prostate Biopsy.
    Eur Urol. 2016 Aug 2. pii: S0302-2838(16)30443.
    PubMed     Text format    


  167. MOSCHINI M, Shariat SF
    Re: Failure-Free Survival and Radiotherapy in Patients with Newly Diagnosed Nonmetastatic Prostate Cancer: Data from Patients in the Control Arm of the STAMPEDE Trial.
    Eur Urol. 2016;70:398-9.
    PubMed     Text format    


    July 2016
  168. FOSSATI N, Karnes RJ, Boorjian SA, Moschini M, et al
    Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.
    Eur Urol. 2016 Jul 30. pii: S0302-2838(16)30433.
    PubMed     Text format     Abstract available


  169. LAZZERI M, Lughezzani G
    Re: Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.
    Eur Urol. 2016 Jul 29. pii: S0302-2838(16)30444.
    PubMed     Text format    


  170. BJARTELL AS
    Re: The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer.
    Eur Urol. 2016 Jul 29. pii: S0302-2838(16)30442.
    PubMed     Text format    


  171. LUDWIG WW, Ross AE, Pierorazio PM
    Local Therapy for Gleason 9-10 Prostate Cancer: Looking to the Future.
    Eur Urol. 2016 Jul 29. pii: S0302-2838(16)30430.
    PubMed     Text format    


  172. STATTIN P, Sandin F, Thomsen FB, Garmo H, et al
    Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study.
    Eur Urol. 2016 Jul 29. pii: S0302-2838(16)30428.
    PubMed     Text format     Abstract available


  173. EIBER M, Herrmann K, Fendler WP, Maurer T, et al
    68Ga-labeled Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Imaging: The New Kid on the Block-Early or Too Early to Draw Conclusions?
    Eur Urol. 2016 Jul 29. pii: S0302-2838(16)30450.
    PubMed     Text format    


  174. BEER TM, Armstrong AJ, Rathkopf D, Loriot Y, et al
    Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.
    Eur Urol. 2016 Jul 28. pii: S0302-2838(16)30437.
    PubMed     Text format     Abstract available


  175. KELLY SP, Rosenberg PS, Anderson WF, Andreotti G, et al
    Trends in the Incidence of Fatal Prostate Cancer in the United States by Race.
    Eur Urol. 2016 Jul 27. pii: S0302-2838(16)30175.
    PubMed     Text format     Abstract available


  176. BERNEMANN C, Schnoeller TJ, Luedeke M, Steinestel K, et al
    Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.
    Eur Urol. 2016 Jul 25. pii: S0302-2838(16)30426.
    PubMed     Text format     Abstract available


  177. BAYNE CE, Williams SB, Chapin BF
    Reply to Lu Yang, Shi Qiu and Qiang Wei's Letter to the Editor re: Christopher E. Bayne, Stephen B. Williams, Matthew R. Cooperberg, et al. Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. Eur Uro
    Eur Urol. 2016 Jul 23. pii: S0302-2838(16)30421.
    PubMed     Text format    


  178. EGEVAD L, Samaratunga H, Srigley JR, Delahunt B, et al
    Re: Anthony Zietman, Joseph Smith, Eric Klein, Michael Droller, Prokar Dasgupta, James Catto. Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. Eur Urol 2016;70:1.
    Eur Urol. 2016 Jul 22. pii: S0302-2838(16)30424.
    PubMed     Text format    


  179. WHITE NM, Zhao SG, Zhang J, Rozycki EB, et al
    Multi-institutional Analysis Shows that Low PCAT-14 Expression Associates with Poor Outcomes in Prostate Cancer.
    Eur Urol. 2016 Jul 22. pii: S0302-2838(16)30417.
    PubMed     Text format     Abstract available


  180. ZIETMAN A, Smith J, Klein E, Droller M, et al
    Reply to Lars Egevad, Hemamali Samaratunga, John R. Srigley, Brett Delahunt's Letter to the Editor re: Anthony Zietman, Joseph Smith, Eric Klein, Michael Droller, Prokar Dasgupta, James Catto. Describing the Grade of Prostate Cancer: Consistent Use of
    Eur Urol. 2016 Jul 21. pii: S0302-2838(16)30425.
    PubMed     Text format    


  181. WEI L, Wang J, Lampert E, Schlanger S, et al
    Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.
    Eur Urol. 2016 Jul 20. pii: S0302-2838(16)30406.
    PubMed     Text format     Abstract available


  182. YANG L, Qiu S, Wei Q
    Re: Christopher E. Bayne, Stephen B. Williams, Matthew R. Cooperberg, et al. Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. Eur Urol 2016;69:775-87.
    Eur Urol. 2016 Jul 20. pii: S0302-2838(16)30423.
    PubMed     Text format    


  183. GILLESSEN S, Gilson C, James N, Adler A, et al
    Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform.
    Eur Urol. 2016 Jul 19. pii: S0302-2838(16)30420.
    PubMed     Text format     Abstract available


  184. TSAO CK, Galsky MD, Oh WK
    Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever.
    Eur Urol. 2016 Jul 11. pii: S0302-2838(16)30393.
    PubMed     Text format     Abstract available


  185. GETTMAN MT
    Thoughts on Criteria for Active Surveillance of Favorable-risk Prostate Cancer.
    Eur Urol. 2016 Jul 11. pii: S0302-2838(16)30384.
    PubMed     Text format    


  186. CULIG Z
    STAT3 in Prostate Cancer: Whom Should We Treat and When?
    Eur Urol. 2016 Jul 8. pii: S0302-2838(16)30386.
    PubMed     Text format    


  187. HU JC, Nanus DM, Sedrakyan A
    Increase in Prostate Cancer Metastases at Radical Prostatectomy in the United States.
    Eur Urol. 2016 Jul 8. pii: S0302-2838(16)30388.
    PubMed     Text format    


  188. DE BONO JS, Smith MR, Saad F, Rathkopf DE, et al
    Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    Eur Urol. 2016 Jul 8. pii: S0302-2838(16)30385.
    PubMed     Text format     Abstract available


  189. CHANG X, Chao Z, Zheng-Yan G
    Re: Alison J. Price, Ruth C. Travis, Paul N. Appleby, et al. Circulating Folate and Vitamin B12 and Risk of Prostate Cancer: A Collaborative Analysis of Individual Participant Data from Six Cohorts Including 6875 Cases and 8104 Controls. Eur Urol. In
    Eur Urol. 2016 Jul 8. pii: S0302-2838(16)30340.
    PubMed     Text format    


  190. LANGE PH
    Re: Intermittent Androgen Deprivation (IAD) in Prostate Cancer (PC): Are We Ready To Quit?
    Eur Urol. 2016 Jul 4. pii: S0302-2838(16)30346.
    PubMed     Text format    


  191. KLIMENT J
    Re: Predicting Prostate Cancer-specific Outcome After Radical Prostatectomy Among Men with Very High-risk cT3b/4 PCa: A Multi-institutional Outcome Study of 266 Patients.
    Eur Urol. 2016 Jul 4. pii: S0302-2838(16)30348.
    PubMed     Text format    


  192. LAMOUREUX F, Thomas C, Yin MJ, Fazli L, et al
    Corrigendum re: "Suppression of Heat Shock Protein 27 Using OGX-427 Induces Endoplasmic Reticulum Stress and Potentiates Heat Shock Protein 90 Inhibitors to Delay Castrate-resistant Prostate Cancer" [Eur Urol 2014;66:145-55].
    Eur Urol. 2016;70:e27-e28.
    PubMed     Text format    


  193. PEARD L, Falkenstrom A, Klaassen Z, Terris MK, et al
    Re: Mental Health Outcomes in Elderly Men with Prostate Cancer.
    Eur Urol. 2016;70:206-7.
    PubMed     Text format    


  194. LUCCA I, Shariat SF
    Re: Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.
    Eur Urol. 2016;70:205-6.
    PubMed     Text format    


  195. WITJES WP
    Re: DNA-repair Defects and Olaparib in Metastatic Prostate Cancer.
    Eur Urol. 2016;70:204-5.
    PubMed     Text format    


  196. DONALDSON JF, McNeill SA
    Re: Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis.
    Eur Urol. 2016 Jul 1. pii: S0302-2838(16)30345.
    PubMed     Text format    


    June 2016
  197. PERERA M, Papa N, Christidis D, Wetherell D, et al
    Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis.
    Eur Urol. 2016 Jun 27. pii: S0302-2838(16)30293.
    PubMed     Text format     Abstract available


  198. MOORE CM, Giganti F, Albertsen P, Allen C, et al
    Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force.
    Eur Urol. 2016 Jun 24. pii: S0302-2838(16)30281.
    PubMed     Text format     Abstract available


  199. PARKER C, Finkelstein SE, Michalski JM, O'Sullivan JM, et al
    Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.
    Eur Urol. 2016 Jun 22. pii: S0302-2838(16)30272.
    PubMed     Text format     Abstract available


  200. DON-DONCOW N, Marginean F, Coleman I, Nelson PS, et al
    Expression of STAT3 in Prostate Cancer Metastases.
    Eur Urol. 2016 Jun 22. pii: S0302-2838(16)30288.
    PubMed     Text format     Abstract available


  201. NEAL D, Lilja H
    Circulating Tumor Cell Count as an Indicator of Treatment Benefit in Advanced Prostate Cancer.
    Eur Urol. 2016 Jun 22. pii: S0302-2838(16)30284.
    PubMed     Text format    


  202. SAITO K
    Local Treatment of the Prostate in Metastatic Prostate Cancer: Need to Change the Concept?
    Eur Urol. 2016 Jun 20. pii: S0302-2838(16)30278.
    PubMed     Text format    


  203. PADHANI AR, Lecouvet FE, Tunariu N, Koh DM, et al
    METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer.
    Eur Urol. 2016 Jun 14. pii: S0302-2838(16)30241.
    PubMed     Text format     Abstract available


  204. RIDER JR, Wilson KM, Mucci LA, Giovannucci EL, et al
    Reply to Cedric Annweiler, Pierre Bigot, and Spyridon N. Karras' Letter to the Editor re: Jennifer R. Rider, Kathryn M. Wilson, Jennifer A. Sinnott, Rachel S. Kelly, Lorelei A. Muccia, Edward L. Giovannucci. Ejaculation Frequency and Risk of Prostate
    Eur Urol. 2016 Jun 14. pii: S0302-2838(16)30263.
    PubMed     Text format    


  205. TOSOIAN JJ, Trock BJ, Ballentine Carter H, Mamawala M, et al
    Reply to Weigang Yan, Zhien Zhou, Hanzhong Li's Letter to the Editor re: Jeffrey J. Tosoian, Debasish Sundi, Bruce J. Trock, et al. Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Imm
    Eur Urol. 2016 Jun 13. pii: S0302-2838(16)30245.
    PubMed     Text format    


  206. WONG MC, Goggins WB, Wang HH, Fung FD, et al
    Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries.
    Eur Urol. 2016 Jun 8. pii: S0302-2838(16)30251.
    PubMed     Text format     Abstract available


  207. LORENTE D, Olmos D, Mateo J, Bianchini D, et al
    Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer.
    Eur Urol. 2016 Jun 8. pii: S0302-2838(16)30187.
    PubMed     Text format     Abstract available


  208. LOEB S, Curnyn C, Sedlander E
    Perspectives of Prostate Cancer Patients on Gleason Scores and the New Grade Groups: Initial Qualitative Study.
    Eur Urol. 2016 Jun 6. pii: S0302-2838(16)30247.
    PubMed     Text format    


  209. ANNWEILER C, Bigot P, Karras SN
    Re: Jennifer R. Rider, Kathryn M. Wilson, Jennifer A. Sinnott, Rachel S. Kelly, Lorelei A. Muccia, Edward L. Giovannucci. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol. In press. ht
    Eur Urol. 2016 Jun 4. pii: S0302-2838(16)30252.
    PubMed     Text format    


  210. YAN W, Zhou Z, Li H
    Re: Jeffrey J. Tosoian, Debasish Sundi, Bruce J. Trock, et al. Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. Eur Urol 2016;69:576-81.
    Eur Urol. 2016 Jun 1. pii: S0302-2838(16)30244.
    PubMed     Text format    


  211. BRATT O
    Re: Risk of Malignant Melanoma in Men with Prostate Cancer. Nationwide, Population-based Cohort Study.
    Eur Urol. 2016;69:1158-9.
    PubMed     Text format    


  212. SCHLOMM T
    Re: The Molecular Taxonomy of Primary Prostate Cancer.
    Eur Urol. 2016;69:1157.
    PubMed     Text format    


  213. STERNBERG CN
    Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial.
    Eur Urol. 2016;69:1155-6.
    PubMed     Text format    


    May 2016
  214. STERNBERG CN
    Improving Survival for Metastatic Castrate-resistant Prostate Cancer: Will Combination Therapy Help Us To Move Forward?
    Eur Urol. 2016 May 30. pii: S0302-2838(16)30199.
    PubMed     Text format    


  215. CONTEDUCA V, Lolli C, De Giorgi U
    Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. In p
    Eur Urol. 2016 May 30. pii: S0302-2838(16)30197.
    PubMed     Text format    


  216. RESCIGNO P, de Bono JS
    Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Sur
    Eur Urol. 2016 May 27. pii: S0302-2838(16)30198.
    PubMed     Text format    


  217. GEYNISMAN DM, Plimack ER, Zibelman M
    Second-generation Androgen Receptor-targeted Therapies in Nonmetastatic Castration-resistant Prostate Cancer: Effective Early Intervention or Intervening Too Early?
    Eur Urol. 2016 May 26. pii: S0302-2838(16)30190.
    PubMed     Text format    


  218. OBEID R, Pietrzik K
    Re: Alison J. Price, Ruth C. Travis, Paul N. Appleby, et al. Circulating Folate and Vitamin B and Risk of Prostate Cancer: A Collaborative Analysis of Individual Participant Data from Six Cohorts Including 6875 Cases and 8104 Controls. Eur Urol. In pr
    Eur Urol. 2016 May 25. pii: S0302-2838(16)30188.
    PubMed     Text format    


  219. WAUGH DJ
    Expanding the Armamentarium for Castrate-resistant Prostate Cancer.
    Eur Urol. 2016 May 24. pii: S0302-2838(16)30186.
    PubMed     Text format    


  220. GARDINER RA, Mainwaring P, Lavin MF
    Integrating Molecular Profiling of Liquid Biopsy Samples with a Calculator Algorithm To Detect High-risk Prostate Cancer.
    Eur Urol. 2016 May 24. pii: S0302-2838(16)30176.
    PubMed     Text format    


  221. GODTMAN RA, Stranne J, Hugosson J
    Reply from Authors re: Roderick C.N. van den Bergh, Declan G. Murphy, Henk G. van der Poel. Expectant Management for Prostate Cancer: Lessons from the Past, Challenges for the Future. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.04.024.
    Eur Urol. 2016 May 19. pii: S0302-2838(16)30159.
    PubMed     Text format    


  222. PAKARAINEN T, Raitanen J, Talala K, Taari K, et al
    Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study.
    Eur Urol. 2016 May 19. pii: S0302-2838(16)30173.
    PubMed     Text format     Abstract available


  223. ALONGI F, Mazzola R, Fersino S
    Re: Patrick C. Walsh, Nathan Lawrentschuk. Immediate Adjuvant Radiation Therapy Following Radical Prostatectomy Should Not Be Advised for Men with Extraprostatic Extension Who Have Negative Surgical Margins. Eur Urol 2016;69:191-2: Personalization of
    Eur Urol. 2016 May 18. pii: S0302-2838(16)30178.
    PubMed     Text format    


  224. FIZAZI K, De Porre P, Londhe A, McGowan T, et al
    Reply to Giandomenico Roviello, Alberto Bottini, and Daniele Generali's Letter to the Editor re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone
    Eur Urol. 2016 May 18. pii: S0302-2838(16)30158.
    PubMed     Text format    


  225. GANDAGLIA G, De Lorenzis E, Novara G, Fossati N, et al
    Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection in Patients with Locally-advanced Prostate Cancer.
    Eur Urol. 2016 May 18. pii: S0302-2838(16)30172.
    PubMed     Text format     Abstract available


  226. FRANCINI E, Sweeney CJ
    Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2016 May 13. pii: S0302-2838(16)30155.
    PubMed     Text format     Abstract available


  227. LOPPENBERG B, Dalela D, Karabon P, Sood A, et al
    The Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis: A National Cancer Data Base Analysis.
    Eur Urol. 2016 May 9. pii: S0302-2838(16)30141.
    PubMed     Text format     Abstract available


  228. SMITH MR, Antonarakis ES, Ryan CJ, Berry WR, et al
    Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
    Eur Urol. 2016 May 5. pii: S0302-2838(16)30133.
    PubMed     Text format     Abstract available


  229. SAEED K, Rahkama V, Eldfors S, Bychkov D, et al
    Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer.
    Eur Urol. 2016 May 5. pii: S0302-2838(16)30080.
    PubMed     Text format     Abstract available


  230. RIDER JR, Wilson KM, Sinnott JA, Kelly RS, et al
    Reply to Herney Andres Garcia-Perdomo and Ramiro Manzano Nunez's Letter to the Editor Re: Jennifer R. Rider, Kathryn M. Wilson, Jennifer M. Sinnott, Rachel S. Kelly, Lorelei A. Mucci, Edward L. Giovannucci. Ejaculation Frequency and Risk of Prostate C
    Eur Urol. 2016 May 4. pii: S0302-2838(16)30142.
    PubMed     Text format    


  231. GARCIA-PERDOMO HA, Manzano Nunez R
    Re: Jennifer R. Rider, Kathryn M. Wilson, Jennifer M. Sinnott, Rachel S. Kelly, Lorelei A. Mucci, Edward L. Giovannucci. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol. In press. htt
    Eur Urol. 2016 May 4. pii: S0302-2838(16)30140.
    PubMed     Text format    


  232. LEAPMAN MS, Ameli N, Cooperberg MR, Chu C, et al
    Quantified Clinical Risk Change as an End Point During Prostate Cancer Active Surveillance.
    Eur Urol. 2016 May 3. pii: S0302-2838(16)30131.
    PubMed     Text format     Abstract available


  233. KEARNS JT
    Corrigendum re: "Associations Between iCOGS Single Nucleotide Polymorphisms and Upgrading in Both Surgical and Active Surveillance Cohorts of Men with Prostate Cancer" [Eur Urol 2016;69:223-8].
    Eur Urol. 2016 May 2. pii: S0302-2838(16)30130.
    PubMed     Text format    


  234. VAN DEN BERGH RC, Murphy DG, van der Poel HG
    Expectant Management for Prostate Cancer: Lessons from the Past, Challenges for the Future.
    Eur Urol. 2016 May 2. pii: S0302-2838(16)30134.
    PubMed     Text format    


  235. DELL'OGLIO P, Suardi N
    Re: Acute Toxicity and Quality of Life After Dose-intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09/10.
    Eur Urol. 2016;69:966.
    PubMed     Text format    


  236. SIMONE G, Anceschi U, Gallucci M
    Re: Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: A Prospective Development Study.
    Eur Urol. 2016;69:965-6.
    PubMed     Text format    


  237. VAN DEN BERGH RC, Zargar H, Murphy DG
    Re: Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery.
    Eur Urol. 2016;69:964-5.
    PubMed     Text format    


    April 2016
  238. RUD E, Baco E
    Re: Jeffrey C. Weinreb, Jelle O. Barentsz, Peter L. Choyke, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol 2016;69:16-40: Is Contrast-enhanced Magnetic Resonance Imaging Really Necessary When Searching for Prost
    Eur Urol. 2016 Apr 25. pii: S0302-2838(16)30076.
    PubMed     Text format    


  239. NEWTON RU, Galvao DA
    Accumulating Evidence for Physical Activity and Prostate Cancer Survival: Time for a Definitive Trial of Exercise Medicine?
    Eur Urol. 2016 Apr 23. pii: S0302-2838(16)30077.
    PubMed     Text format    


  240. WELTI J, Rodrigues DN, Sharp A, Sun S, et al
    Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2016 Apr 22. pii: S0302-2838(16)30027.
    PubMed     Text format     Abstract available


  241. VAN NESTE L, Hendriks RJ, Dijkstra S, Trooskens G, et al
    Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
    Eur Urol. 2016 Apr 20. pii: S0302-2838(16)30071.
    PubMed     Text format     Abstract available


  242. GULATI R, Etzioni R
    A Matched Cohort Analysis of Prostate Cancer Screening in Younger Men in Sweden.
    Eur Urol. 2016 Apr 15. pii: S0302-2838(16)30065.
    PubMed     Text format    


  243. GODTMAN RA, Holmberg E, Khatami A, Pihl CG, et al
    Long-term Results of Active Surveillance in the Goteborg Randomized, Population-based Prostate Cancer Screening Trial.
    Eur Urol. 2016 Apr 15. pii: S0302-2838(16)30026.
    PubMed     Text format     Abstract available


  244. LOEB S
    Will Changes to Prostate Cancer Screening Guidelines Preserve Benefits and Reduce Harm?
    Eur Urol. 2016 Apr 15. pii: S0302-2838(16)30025.
    PubMed     Text format    


  245. LI H, Yan W, Ji Z
    Re: Hashim U. Ahmed, Louise Dickinson, Susan Charman, et al. Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: a Prospective Development Study. Eur Urol 2015;68:927-36.
    Eur Urol. 2016 Apr 13. pii: S0302-2838(16)30028.
    PubMed     Text format    


  246. CARLSSON S, Assel M, Ulmert D, Gerdtsson A, et al
    Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.
    Eur Urol. 2016 Apr 12. pii: S0302-2838(16)00376.
    PubMed     Text format     Abstract available


  247. PRICE AJ, Travis RC, Appleby PN, Albanes D, et al
    Circulating Folate and Vitamin B and Risk of Prostate Cancer: A Collaborative Analysis of Individual Participant Data from Six Cohorts Including 6875 Cases and 8104 Controls.
    Eur Urol. 2016 Apr 6. pii: S0302-2838(16)00379.
    PubMed     Text format     Abstract available


  248. WALZ J
    Re: Comparison of MR/Ultrasound Fusion-Guided Biopsy With Ultrasound-guided Biopsy for the Diagnosis of Prostate Cancer.
    Eur Urol. 2016;69:756-7.
    PubMed     Text format    


  249. MATHIEU R, Shariat SF
    Re: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
    Eur Urol. 2016;69:755-6.
    PubMed     Text format    


  250. KIMURA T, Egawa S
    Re: Randomized Controlled Trial of Early Zoledronic Acid in Men with Castration-sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance).
    Eur Urol. 2016;69:754-5.
    PubMed     Text format    


  251. LARCHER A, Fossati N, Dell'Oglio P, Montorsi F, et al
    Reply from Authors re: Matthew C. Hayes, David J. Breen. Excision Versus Ablation in Renal Cancer: Optimising Outcome and Minimising Risk. Eur Urol 2016;69:683-4.
    Eur Urol. 2016;69:684-5.
    PubMed     Text format    


  252. ALBERTSEN PC
    Another Reason to Consider Active Surveillance.
    Eur Urol. 2016;69:582-3.
    PubMed     Text format    


  253. DAL PRA A, Spahn M
    Re: William C. Jackson, Matthew J. Schipper, Skyler B. Johnson, et al. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Eur Urol 2016;69:50-7. Re: Ronald C. Chen. Po
    Eur Urol. 2016;69:e74-5.
    PubMed     Text format    


  254. HAMILTON ZA, Kane CJ
    Nerve-sparing Technique During Radical Prostatectomy and its Effect on Urinary Continence.
    Eur Urol. 2016;69:590-1.
    PubMed     Text format    


    March 2016
  255. RIDER JR, Wilson KM, Sinnott JA, Kelly RS, et al
    Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up.
    Eur Urol. 2016 Mar 28. pii: S0302-2838(16)00377.
    PubMed     Text format     Abstract available


  256. EVANGELISTA L, Fanti S, Picchio M
    Reply to Egesta Lopci, Arturo Chiti, and Massimo Lazzeri's Letter to the Editor re: Laura Evangelista, Alberto Briganti, Stefano Fanti, et al. New Clinical Indications for F/C-choline, New Tracers for Positron Emission Tomography and a Promising Hybri
    Eur Urol. 2016 Mar 26. pii: S0302-2838(16)00374.
    PubMed     Text format    


  257. FOSSA SD, Wiklund F, Klepp O, Angelsen A, et al
    Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandina
    Eur Urol. 2016 Mar 26. pii: S0302-2838(16)00278.
    PubMed     Text format     Abstract available


  258. LOPCI E, Chiti A, Lazzeri M
    Re: Laura Evangelista, Alberto Briganti, Stefano Fanti, et al. New Clinical Indications for F/C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. Eur
    Eur Urol. 2016 Mar 25. pii: S0302-2838(16)00375.
    PubMed     Text format    


  259. VAN STAM MA, Aaronson NK, Pos FJ, Bosch JL, et al
    The Effect of Salvage Radiotherapy and its Timing on the Health-related Quality of Life of Prostate Cancer Patients.
    Eur Urol. 2016 Mar 22. pii: S0302-2838(16)00267.
    PubMed     Text format     Abstract available


  260. ZIETMAN A, Smith J, Klein E, Droller M, et al
    Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required.
    Eur Urol. 2016 Mar 21. pii: S0302-2838(16)00264.
    PubMed     Text format    


  261. EVANS CP, Higano CS, Keane T, Andriole G, et al
    The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2016 Mar 19. pii: S0302-2838(16)00274.
    PubMed     Text format     Abstract available


  262. SHOAG J, Mittal S, Halpern JA, Scherr D, et al
    Lethal Prostate Cancer in the PLCO Cancer Screening Trial.
    Eur Urol. 2016 Mar 17. pii: S0302-2838(16)00060.
    PubMed     Text format     Abstract available


  263. FOSSATI N, Gandaglia G, Bossi A, Montorsi F, et al
    Re: Stephen J. Freedland, Voleak Choeurng, Lauren Howard, et al. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2
    Eur Urol. 2016 Mar 15. pii: S0302-2838(16)00269.
    PubMed     Text format    


  264. FIZAZI K, Chi KN, de Bono JS, Gomella LG, et al
    Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2016 Mar 7. pii: S0302-2838(16)00213.
    PubMed     Text format     Abstract available


  265. RESCIGNO P, Lorente D, Bianchini D, Ferraldeschi R, et al
    Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2016 Mar 7. pii: S0302-2838(16)00245.
    PubMed     Text format     Abstract available


  266. TOUIJER KA, Eastham JA
    The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer.
    Eur Urol. 2016 Mar 5. pii: S0302-2838(16)00237.
    PubMed     Text format    


  267. DICKINSON L, Arya M, Afzal N, Cathcart P, et al
    Medium-term Outcomes after Whole-gland High-intensity Focused Ultrasound for the Treatment of Nonmetastatic Prostate Cancer from a Multicentre Registry Cohort.
    Eur Urol. 2016 Mar 4. pii: S0302-2838(16)00244.
    PubMed     Text format     Abstract available


  268. MURPHY DG, Zargar H
    Re: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
    Eur Urol. 2016;69:540.
    PubMed     Text format    


  269. CHAN J, Roach M
    Words of Wisdom. Re: Genomic Classifier Identifies Men with Adverse Pathology After Radical Prostatectomy Who Benefit from Adjuvant Radiation Therapy.
    Eur Urol. 2016;69:539-40.
    PubMed     Text format    


  270. AHMAD AE, Finelli A
    Should Prebiopsy Multiparametric Magnetic Resonance Imaging be Offered to All Biopsy-naive Men Undergoing Prostate Biopsy?
    Eur Urol. 2016;69:426-7.
    PubMed     Text format    


  271. PORPIGLIA F, Bertolo R, Manfredi M, De Luca S, et al
    Total Anatomical Reconstruction During Robot-assisted Radical Prostatectomy: Implications on Early Recovery of Urinary Continence.
    Eur Urol. 2016;69:485-95.
    PubMed     Text format     Abstract available


  272. MENG X, Rosenkrantz AB, Mendhiratta N, Fenstermaker M, et al
    Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes.
    Eur Urol. 2016;69:512-7.
    PubMed     Text format     Abstract available


  273. GIANNARINI G, Briganti A, Crestani A, Rossanese M, et al
    Dismiss Systematic Transrectal Ultrasound-guided and Embrace Targeted Magnetic Resonance Imaging-informed Prostate Biopsy: Is the Paradigm Ready to Shift?
    Eur Urol. 2016;69:381-3.
    PubMed     Text format    


  274. BRAUN K, Sjoberg DD, Vickers AJ, Lilja H, et al
    A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.
    Eur Urol. 2016;69:505-11.
    PubMed     Text format     Abstract available


  275. ROSS AE, Yousefi K, Davicioni E, Ghadessi M, et al
    Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men.
    Eur Urol. 2016;69:496-504.
    PubMed     Text format     Abstract available


    February 2016
  276. BARBOSA PV, Thomas IC, Srinivas S, Buyyounouski MK, et al
    Overall Survival in Patients with Localized Prostate Cancer in the US Veterans Health Administration: Is PIVOT Generalizable?
    Eur Urol. 2016 Feb 29. pii: S0302-2838(16)00215.
    PubMed     Text format     Abstract available


  277. TREE AC, van As NJ, Dearnaley DP
    Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.11.010.
    Eur Urol. 2016 Feb 29. pii: S0302-2838(16)00222.
    PubMed     Text format    


  278. REIG O, Marin-Aguilera M, Carrera G, Jimenez N, et al
    TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2016 Feb 29. pii: S0302-2838(16)00212.
    PubMed     Text format     Abstract available


  279. LAZAR AA, Lizarraga TL, Roach M 3rd
    Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.11.010: Radical Pr
    Eur Urol. 2016 Feb 27. pii: S0302-2838(16)00220.
    PubMed     Text format    


  280. FROEHNER M, Wirth MP
    Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.11.010.
    Eur Urol. 2016 Feb 27. pii: S0302-2838(16)00221.
    PubMed     Text format    


  281. OST P, Ghadjar P
    Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.11.010.
    Eur Urol. 2016 Feb 26. pii: S0302-2838(16)00219.
    PubMed     Text format    


  282. PARKER C
    Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.11.010.
    Eur Urol. 2016 Feb 26. pii: S0302-2838(16)00217.
    PubMed     Text format    


  283. WALLIS CJ, Nam RK
    Reply from Authors re: Martin Spahn, Alan Dal Pra, Daniel Aebersold, Bertrand Tombal. Radiation Therapy Versus Radical Prostatectomy: A Never-ending Discussion. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.01.049: Prostate Cancer Treatm
    Eur Urol. 2016 Feb 25. pii: S0302-2838(16)00216.
    PubMed     Text format    


  284. BLANCHARD P, Briganti A, Bossi A
    Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.11.010.
    Eur Urol. 2016 Feb 24. pii: S0302-2838(16)00218.
    PubMed     Text format    


  285. GANDAGLIA G, Briganti A, Fossati N, Salonia A, et al
    The Problem Is Not What to Do with Indolent and Harmless Prostate Cancer-The Problem Is How to Avoid Finding These Cancers.
    Eur Urol. 2016 Feb 22. pii: S0302-2838(16)00210.
    PubMed     Text format     Abstract available


  286. MARTIN NE, Stowell C
    Reply to Daniela Wittmann, Ted A. Skolarus' Letter to the Editor re: Neil E. Martin, Laura Massey, Caleb Stowell, et al. Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. Eur Urol 2014;67:460-7.
    Eur Urol. 2016 Feb 9. pii: S0302-2838(16)00160.
    PubMed     Text format    


  287. WITTMANN D, Skolarus TA
    Re: Neil E. Martin, Laura Massey, Caleb Stowell, et al. Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. Eur Urol 2015;67:460-7.
    Eur Urol. 2016 Feb 9. pii: S0302-2838(16)00161.
    PubMed     Text format    


  288. THOMPSON IM JR, Ankerst DP
    The Role of Magnetic Resonance Imaging in Prostate Cancer: Focusing on What Really Matters.
    Eur Urol. 2016 Feb 6. pii: S0302-2838(16)00158.
    PubMed     Text format    


  289. NGUYEN DP, Huber PM, Metzger TA, Genitsch V, et al
    A Specific Mapping Study Using Fluorescence Sentinel Lymph Node Detection in Patients with Intermediate- and High-risk Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection.
    Eur Urol. 2016 Feb 4. pii: S0302-2838(16)00136.
    PubMed     Text format     Abstract available


  290. TAGAWA ST, Posadas EM, Bruce J, Lim EA, et al
    Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2016 Feb 3. pii: S0302-2838(16)00130.
    PubMed     Text format     Abstract available


  291. EVANGELISTA L, Briganti A, Fanti S, Joniau S, et al
    New Clinical Indications for F/C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
    Eur Urol. 2016 Feb 2. pii: S0302-2838(16)00131.
    PubMed     Text format     Abstract available


  292. ISBARN H
    Re: Androgen Deprivation With or Without Radiation Therapy for Clinically Node-Positive Prostate Cancer.
    Eur Urol. 2016;69:372-3.
    PubMed     Text format    


  293. GANDAGLIA G, Briganti A, Montorsi F
    Re: Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men with Favorable Intermediate-risk Prostate Cancer.
    Eur Urol. 2016;69:370.
    PubMed     Text format    


  294. BESSEDE T, Patard JJ
    Words of Wisdom. Re: The Use of Early Postoperative Prostate-specific Antigen to Stratify Risk in Patients with Positive Surgical Margins After Radical Prostatectomy.
    Eur Urol. 2016;69:372.
    PubMed     Text format    


  295. COOPER CS, Clark J, Brewer DS, Edwards DR, et al
    Prostate Single Nucleotide Polymorphism Provides a Crucial Clue to Cancer Aggression in Active Surveillance Patients.
    Eur Urol. 2016;69:229-30.
    PubMed     Text format    


  296. WALSH PC, Lawrentschuk N
    Immediate Adjuvant Radiation Therapy Following Radical Prostatectomy Should Not Be Advised for Men with Extraprostatic Extension Who Have Negative Surgical Margins.
    Eur Urol. 2016;69:191-2.
    PubMed     Text format     Abstract available


  297. SHIN T, Ukimura O, Gill IS
    Three-dimensional Printed Model of Prostate Anatomy and Targeted Biopsy-proven Index Tumor to Facilitate Nerve-sparing Prostatectomy.
    Eur Urol. 2016;69:377-9.
    PubMed     Text format    


  298. MOSCHINI M, Briganti A, Murphy CR, Bianchi M, et al
    Outcomes for Patients with Clinical Lymphadenopathy Treated with Radical Prostatectomy.
    Eur Urol. 2016;69:193-6.
    PubMed     Text format     Abstract available


    January 2016
  299. PISANSKY TM
    Salvage Radiotherapy for Postoperative Biochemical Failure of Prostate Cancer: The Path Toward Personalized Medicine.
    Eur Urol. 2016 Jan 29. pii: S0302-2838(16)00135.
    PubMed     Text format    


  300. FABRIS L, Ceder Y, Chinnaiyan AM, Jenster GW, et al
    The Potential of MicroRNAs as Prostate Cancer Biomarkers.
    Eur Urol. 2016 Jan 21. pii: S0302-2838(16)00012.
    PubMed     Text format     Abstract available


  301. LEPOR H
    The Challenge for Urologists Is to Screen, Detect, and Treat Prostate Cancer "Smarter": Will Ablative Technology Result in Smarter Treatment?
    Eur Urol. 2016 Jan 20. pii: S0302-2838(16)00075.
    PubMed     Text format    


  302. HERLEMANN A, Wenter V, Kretschmer A, Thierfelder KM, et al
    Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer.
    Eur Urol. 2016 Jan 19. pii: S0302-2838(16)00009.
    PubMed     Text format     Abstract available


  303. EIBER M, Weirich G, Holzapfel K, Souvatzoglou M, et al
    Simultaneous Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer.
    Eur Urol. 2016 Jan 18. pii: S0302-2838(16)00011.
    PubMed     Text format     Abstract available


  304. YOSHIMURA K, Minami T, Nozawa M, Kimura T, et al
    A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer.
    Eur Urol. 2016 Jan 15. pii: S0302-2838(16)00008.
    PubMed     Text format     Abstract available


  305. CARAM ME, Skolarus TA, Cooney KA
    Limitations of Prostate-specific Antigen Testing After a Prostate Cancer Diagnosis.
    Eur Urol. 2016 Jan 14. pii: S0302-2838(15)01265.
    PubMed     Text format     Abstract available


  306. FRIEDENREICH CM, Wang Q, Neilson HK, Kopciuk KA, et al
    Physical Activity and Survival After Prostate Cancer.
    Eur Urol. 2016 Jan 7. pii: S0302-2838(15)01241.
    PubMed     Text format     Abstract available


  307. CHIN JL, Billia M, Relle J, Roethke MC, et al
    Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial.
    Eur Urol. 2016 Jan 6. pii: S0302-2838(15)01238.
    PubMed     Text format     Abstract available


  308. SIVARAMAN A, Barret E
    Focal Therapy for Prostate Cancer: An "A la Carte" Approach.
    Eur Urol. 2016 Jan 5. pii: S0302-2838(15)01223.
    PubMed     Text format     Abstract available


  309. DE REIJKE T
    Words of Wisdom: Re: Chemohormonal Therapy in Metastatic Hormone-sensitive Prostate Cancer.
    Eur Urol. 2016;69:178.
    PubMed     Text format    


  310. PINTHUS J, Morris C
    Words or Wisdom: Re: The Incidence and Relative Risk of Cardiovascular Toxicity in Patients Treated with New Hormonal Agents for Castration-resistant Prostate Cancer.
    Eur Urol. 2016;69:177-8.
    PubMed     Text format    


  311. LAZZERI M, Guazzoni G
    Words of Wisdom: Re: Shift Work and Prostate Cancer Incidence in Industrial Workers: A Historical Cohort Study in a German Chemical Company.
    Eur Urol. 2016;69:175-6.
    PubMed     Text format    


  312. THOMAS JA, Bachmann A
    Reply from Authors re: Jean-Nicolas Cornu, Stephan Madersbacher. Greenlight Photovaporisation of the Prostate: Now Ready for Prime Time. Eur Urol 2016;69:103-4.
    Eur Urol. 2016;69:105-6.
    PubMed     Text format    


  313. CHEN RC
    Postprostatectomy Radiotherapy: Whether and How Long to Give Concurrent Androgen Deprivation Therapy.
    Eur Urol. 2016;69:58-9.
    PubMed     Text format    


    December 2015
  314. GREY A
    Osteoporosis and Fracture Risk in Men with Prostate Cancer.
    Eur Urol. 2015 Dec 31. pii: S0302-2838(15)01256.
    PubMed     Text format    


  315. BIANCHI L, Nini A, Bianchi M, Gandaglia G, et al
    The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Eur Urol. 2015 Dec 31. pii: S0302-2838(15)01218.
    PubMed     Text format     Abstract available


  316. LOEB S, Folkvaljon Y, Robinson D, Schlomm T, et al
    Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.
    Eur Urol. 2015 Dec 29. pii: S0302-2838(15)01221.
    PubMed     Text format     Abstract available


  317. GRENABO BERGDAHL A, Wilderang U, Aus G, Carlsson S, et al
    Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Goteborg Randomised Screening Trial.
    Eur Urol. 2015 Dec 24. pii: S0302-2838(15)01214.
    PubMed     Text format     Abstract available


  318. CHENG HH, Pritchard CC, Boyd T, Nelson PS, et al
    Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2015 Dec 23. pii: S0302-2838(15)01177.
    PubMed     Text format     Abstract available


  319. MEHRA R, Udager AM, Ahearn TU, Cao X, et al
    Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer.
    Eur Urol. 2015 Dec 23. pii: S0302-2838(15)01211.
    PubMed     Text format     Abstract available


  320. KAPLAN AL, Hu JC, Morgentaler A, Mulhall JP, et al
    Testosterone Therapy in Men With Prostate Cancer.
    Eur Urol. 2015 Dec 21. pii: S0302-2838(15)01213.
    PubMed     Text format     Abstract available


  321. TILKI D, Evans CP
    Hormonal Treatment for Nonmetastatic Disease Recurrence After Curative Treatment of Prostate Cancer: Only for a Select Few.
    Eur Urol. 2015 Dec 21. pii: S0302-2838(15)01216.
    PubMed     Text format    


  322. BRYANT HE
    The Clinical Impact of BRCA2 Loss in Prostate Cancer.
    Eur Urol. 2015 Dec 18. pii: S0302-2838(15)01217.
    PubMed     Text format    


  323. LANGLEY RE, Kynaston HG, Alhasso AA, Duong T, et al
    A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol.
    Eur Urol. 2015 Dec 17. pii: S0302-2838(15)01201.
    PubMed     Text format     Abstract available


  324. ALBERTSEN PC, Lu-Yao GL
    Reply to Michael Froehner, Rainer Koch, Manfred P. Wirth's Letter to the Editor re: Grace L. Lu-Yao, Peter C. Albertsen, Dirk F. Moore, Yong Lin, Robert S. DiPaola, Siu-Long Yao. Fifteen-year Outcomes Following Conservative Management Among Men Aged 6
    Eur Urol. 2015 Dec 16. pii: S0302-2838(15)01202.
    PubMed     Text format    


  325. YAP T, Ahmed HU, Hindley RG, Guillaumier S, et al
    Reply from Authors re: Giorgio Gandaglia, Alberto Briganti, Andrea Salonia, Francesco Montorsi. Excellent Erectile Function Recovery after Focal Therapy: Is This Enough? Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.11.014: Focal Therapy
    Eur Urol. 2015 Dec 13. pii: S0302-2838(15)01208.
    PubMed     Text format    


  326. VAN DEN BERGH RC, van Casteren NJ, van den Broeck T, Fordyce ER, et al
    Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review.
    Eur Urol. 2015 Dec 12. pii: S0302-2838(15)01178.
    PubMed     Text format     Abstract available


  327. HENDERSON DR, de Souza NM, Parker CC, van As NJ, et al
    Reply from Authors re: Tillmann Loch, Pat Fox Fulgham. Active Surveillance Challenges in Men with Prostate Cancer: Role of Imaging Today and Tomorrow. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.11.015: Imaging in Active Surveillance f
    Eur Urol. 2015 Dec 11. pii: S0302-2838(15)01188.
    PubMed     Text format    


  328. SRIDHAR SS, Sweeney CJ
    It Is Time to Harmonize the Design and Conduct of Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer.
    Eur Urol. 2015 Dec 9. pii: S0302-2838(15)01186.
    PubMed     Text format    


  329. FROEHNER M, Koch R, Wirth MP
    Re: Grace L. Lu-Yao, Peter C. Albertsen, Dirk F. Moore, Yong Lin, Robert S. DiPaola, Siu-Long Yao. Fifteen-year Outcomes Following Conservative Management Among Men aged 65 Years or Older with Localized Prostate Cancer. Eur Urol 2015;68:805-11.
    Eur Urol. 2015 Dec 9. pii: S0302-2838(15)01203.
    PubMed     Text format    


  330. IGLESIAS-GATO D, Wikstrom P, Tyanova S, Lavallee C, et al
    The Proteome of Primary Prostate Cancer.
    Eur Urol. 2015 Dec 2. pii: S0302-2838(15)01087.
    PubMed     Text format     Abstract available


  331. LOCH T, Fulgham PF
    Active Surveillance Challenges in Men with Prostate Cancer: Role of Imaging Today and Tomorrow.
    Eur Urol. 2015 Dec 1. pii: S0302-2838(15)01165.
    PubMed     Text format    


    November 2015
  332. WALLIS CJ, Saskin R, Choo R, Herschorn S, et al
    Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis.
    Eur Urol. 2015 Nov 30. pii: S0302-2838(15)01160.
    PubMed     Text format     Abstract available


  333. BOURKE L, Smith D, Steed L, Hooper R, et al
    Exercise for Men with Prostate Cancer: A Systematic Review and Meta-analysis.
    Eur Urol. 2015 Nov 26. pii: S0302-2838(15)01081.
    PubMed     Text format     Abstract available


  334. KHANI F, Robinson BD
    A "Chicken or Egg" Conundrum: Race, Molecular Subtype, and Tumor Location in Prostate Cancer.
    Eur Urol. 2015 Nov 25. pii: S0302-2838(15)01162.
    PubMed     Text format    


  335. GRAVIS G, Boher JM, Joly F, Soulie M, et al
    Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.
    Eur Urol. 2015 Nov 20. pii: S0302-2838(15)01103.
    PubMed     Text format     Abstract available


  336. EGEVAD L, Delahunt B, Samaratunga H, Srigley JR, et al
    Utility of Reporting the Percentage of High-grade Prostate Cancer.
    Eur Urol. 2015 Nov 19. pii: S0302-2838(15)01158.
    PubMed     Text format    


  337. SHAW GL, Whitaker H, Corcoran M, Dunning MJ, et al
    The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer.
    Eur Urol. 2015 Nov 10. pii: S0302-2838(15)01076.
    PubMed     Text format     Abstract available


  338. WALLIS CJ, Mahar A, Cheung P, Herschorn S, et al
    New Rates of Interventions to Manage Complications of Modern Prostate Cancer Treatment in Older Men.
    Eur Urol. 2015 Nov 10. pii: S0302-2838(15)01077.
    PubMed     Text format     Abstract available


  339. RUBIN MA, Girelli G, Demichelis F
    Genomic Correlates to the Newly Proposed Grading Prognostic Groups for Prostate Cancer.
    Eur Urol. 2015 Nov 9. pii: S0302-2838(15)01074.
    PubMed     Text format     Abstract available


  340. BOLLA M
    Re: Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them.
    Eur Urol. 2015;68:909-10.
    PubMed     Text format    


    September 2015
  341. LA VECCHIA C
    Finasteride and Bladder Cancer.
    Eur Urol. 2015 Sep 10. pii: S0302-2838(15)00858.
    PubMed     Text format    


  342. FAURE WALKER N, Nair R, Anderson C
    Re: Gunnar Steineck, Anders Bjartell, Jonas Hugosson, et al. Degree of preservation of the neurovascular bundles during radical prostatectomy and urinary continence 1 year after surgery. Eur Urol 2015;67:559-68.
    Eur Urol. 2015;68:e63.
    PubMed     Text format    


    August 2015
  343. IRANI J
    Re: Disease Control Outcomes from Analysis of Pooled Individual Patient Data from Five Comparative Randomized Clinical Trials of Degarelix Versus Luteinising Hormone-releasing Hormone Agonists.
    Eur Urol. 2015;68:339.
    PubMed     Text format    


    July 2015
  344. KAMRAVA M
    Re: Ian A. Donaldson, Roberto Alonzi, Dean Barratt, et al. Focal Therapy: Patients, Interventions, and Outcomes-A Report from a Consensus Meeting. Eur Urol 2015;67:771-7.
    Eur Urol. 2015;68:e14.
    PubMed     Text format    


  345. TILKI D, Huland H, Graefen M
    Centralization and Quality Control of Elective Surgery Improve Outcome: Aren't We Ethically Obliged to Force the Pace of Creating High-volume Centers?
    Eur Urol. 2015;68:30-1.
    PubMed     Text format    


  346. AUTORINO R, Zargar H, Porpiglia F
    Reply to Francesco Montorsi and Giorgio Gandaglia's Letter to the Editor re: Riccardo Autorino, Homayoun Zagar, Mirandolino B. Mariano, et al. Perioperative Outcomes of Robotic and Laparoscopic Simple Prostatectomy: A European-American Multi-instituti
    Eur Urol. 2015;68:e9-10.
    PubMed     Text format    


  347. MONTORSI F, Gandaglia G
    Re: Riccardo Autorino, Homayoun Zagar, Mirandolino B. Mariano, et al. Perioperative Outcomes of Robotic and Laparoscopic Simple Prostatectomy: A European-American Multi-institutional Analysis. Eur Urol 2015;68:86-94Re: Matthew Bultitude, Ben Challacom
    Eur Urol. 2015;68:e7-8.
    PubMed     Text format    


  348. BULTITUDE M, Challacombe B
    Simple Prostatectomy: A Step Too Far for Laparoscopy?
    Eur Urol. 2015;68:95-6.
    PubMed     Text format    


  349. AUTORINO R, Zargar H, Mariano MB, Sanchez-Salas R, et al
    Perioperative Outcomes of Robotic and Laparoscopic Simple Prostatectomy: A European-American Multi-institutional Analysis.
    Eur Urol. 2015;68:86-94.
    PubMed     Text format     Abstract available


  350. LOEB S
    Is Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy Ready for "Prime Time"?
    Eur Urol. 2015;68:20-1.
    PubMed     Text format    


    May 2015
  351. NGUYEN PL, Alibhai SM, Basaria S, D'Amico AV, et al
    Adverse effects of androgen deprivation therapy and strategies to mitigate them.
    Eur Urol. 2015;67:825-36.
    PubMed     Text format     Abstract available


  352. ABDOLLAH F, Briganti A, Montorsi F, Stenzl A, et al
    Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy.
    Eur Urol. 2015;67:839-49.
    PubMed     Text format     Abstract available


    April 2015
  353. DASGUPTA P
    Improving the evidence for robot-assisted radical prostatectomy.
    Eur Urol. 2015;67:671-2.
    PubMed     Text format    


  354. HOGLUND M
    Heterogeneous challenges for urologic cancers.
    Eur Urol. 2015;67:738-9.
    PubMed     Text format    


  355. WALLERSTEDT A, Tyritzis SI, Thorsteinsdottir T, Carlsson S, et al
    Short-term results after robot-assisted laparoscopic radical prostatectomy compared to open radical prostatectomy.
    Eur Urol. 2015;67:660-70.
    PubMed     Text format     Abstract available


    March 2015
  356. HAGLIND E, Carlsson S, Stranne J, Wallerstedt A, et al
    Urinary Incontinence and Erectile Dysfunction After Robotic Versus Open Radical Prostatectomy: A Prospective, Controlled, Nonrandomised Trial.
    Eur Urol. 2015 Mar 11. pii: S0302-2838(15)00194.
    PubMed     Text format     Abstract available


  357. VAN ALLEN EM, Garraway LA, Rosenberg JE
    Re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/
    Eur Urol. 2015 Mar 11. pii: S0302-2838(15)00209.
    PubMed     Text format    


  358. STEINECK G, Bjartell A, Hugosson J, Axen E, et al
    Degree of preservation of the neurovascular bundles during radical prostatectomy and urinary continence 1 year after surgery.
    Eur Urol. 2015;67:559-68.
    PubMed     Text format     Abstract available


  359. EHDAIE B, Eastham JA
    Standardization of patient-centered outcomes: less is more.
    Eur Urol. 2015;67:468-9.
    PubMed     Text format    


  360. ZLOTTA AR, Kuk C
    Positive surgical margins: race or surgeon?
    Eur Urol. 2015;67:458-9.
    PubMed     Text format    


  361. ALEMOZAFFAR M, Sanda M, Yecies D, Mucci LA, et al
    Benchmarks for operative outcomes of robotic and open radical prostatectomy: results from the Health Professionals Follow-up Study.
    Eur Urol. 2015;67:432-8.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: